|
summary: This review summarises the data on natalizumab (Tysabri), a recently introduced new treatment for severe relapsing remitting MS. Whilst it is very effective, there is a small risk of serious side effects.
authors: Engelhardt B, Kappos L.
source: Neurodegener Dis. 2008;5(1):16-22.
weblink: click here
related research news: click here
glossary:
Integrin
Multiple sclerosis
Relapsing/remitting MS
Sclerosis
|
